Biotech giant Gilead Sciences, Inc. GILD has put up a steady performance in 2024 amid a volatile market. Its shares have ...

Gilead Sciences will no longer provide four HIV medicines for free as part of a patient assistance program starting at the ...

Shares of Assembly Biosciences (NASDAQ:ASMB) traded higher on Thursday after Gilead Sciences (NASDAQ:GILD) agreed to increase ...

Gilead is going to start testing a drug it believes could prevent HIV infection with just a single shot every year.

Science magazine has chosen twice-yearly lenacapavir PrEP as its 2024 Breakthrough of the Year, recognizing it as a ...

Gilead Sciences’ top money maker Biktarvy has been the company’s crown jewel for years now, but with the HIV med inching ...

Terray is ending the year on a high. Just two short months ago the biotech came out with a healthy $120 million series B ...

Investors are bullish on Gilead as the stock surges on successful launches and strong financial health, offering potential ...

At the HIV Analyst & Investor Event on Tuesday, Gilead Sciences Inc. (NASDAQ:GILD) revealed that it is developing a ...

Gilead Sciences said on Thursday it has appointed Sanofi's Dietmar Berger as its chief medical officer, replacing incumbent ...

Gilead Sciences (GILD) closed the most recent trading day at $91.09, moving +0.44% from the previous trading session. The stock's change was more than the S&P 500's daily loss of 0.09%.

Biotech giant Gilead Sciences, Inc. GILD has put up a steady performance in 2024 amid a volatile market. Its shares have gained 15.4% in a year against the industry’s decline of 10.8%.